发布求助
文献互助 智能选刊 最新文献

Trends in Endocrinology and Metabolism最新文献

筛选
英文 中文
l-Lactate. l-Lactate。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-02 DOI: 10.1016/j.tem.2025.03.001
Ruilong Liu, Yingming Zhao
{"title":"l-Lactate.","authors":"Ruilong Liu, Yingming Zhao","doi":"10.1016/j.tem.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.001","url":null,"abstract":"","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies. 代谢手术和基于 GLP-1 受体激动剂的疗法对保护心脏的益处。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2024-08-10 DOI: 10.1016/j.tem.2024.07.012
Arianne Morissette, Erin E Mulvihill
{"title":"Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies.","authors":"Arianne Morissette, Erin E Mulvihill","doi":"10.1016/j.tem.2024.07.012","DOIUrl":"10.1016/j.tem.2024.07.012","url":null,"abstract":"<p><p>Individuals with excessive adipose tissue and type 2 diabetes mellitus (T2DM) face a heightened risk of cardiovascular morbidity and mortality. Metabolic surgery is an effective therapy for people with severe obesity to achieve significant weight loss. Additionally, metabolic surgery improves blood glucose levels and can lead to T2DM remission, reducing major adverse cardiovascular outcomes (MACE). Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medication that effectively reduce body weight and MACE in patients with T2DM. This review explores the potential mechanisms underlying the cardioprotective benefits of metabolic surgery and GLP-1RA-based therapies and discusses recent evidence and emerging therapies in this dynamic area of research.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"316-329"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like peptide-1. Glucagon-like peptide-1。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2025-01-15 DOI: 10.1016/j.tem.2024.12.011
Darleen A Sandoval
{"title":"Glucagon-like peptide-1.","authors":"Darleen A Sandoval","doi":"10.1016/j.tem.2024.12.011","DOIUrl":"10.1016/j.tem.2024.12.011","url":null,"abstract":"","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"386-387"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The direct targets of metformin in diabetes and beyond. 二甲双胍在糖尿病及其他疾病中的直接靶点。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2024-09-02 DOI: 10.1016/j.tem.2024.07.017
Luxia Yao, Lei Wang, Runshuai Zhang, Alexander A Soukas, Lianfeng Wu
{"title":"The direct targets of metformin in diabetes and beyond.","authors":"Luxia Yao, Lei Wang, Runshuai Zhang, Alexander A Soukas, Lianfeng Wu","doi":"10.1016/j.tem.2024.07.017","DOIUrl":"10.1016/j.tem.2024.07.017","url":null,"abstract":"<p><p>Metformin, an oral antihyperglycemic drug that has been in use for over 60 years, remains a first-line therapy for type 2 diabetes (T2D). Numerous studies have suggested that metformin promotes health benefits beyond T2D management, including weight loss, cancer prevention and treatment, and anti-aging, through several proposed mechanistic targets. Here we discuss the established effects of metformin and the progress made in identifying its direct targets. Additionally, we emphasize the importance of elucidating the structural bases of the drug and its direct targets. Ultimately, this review aims to highlight the current state of knowledge regarding metformin and its related emerging discoveries, while also outlining critical future research directions.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"364-372"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancer binding as a KEysTONE of fasting response. 增强子结合是禁食反应的关键。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2025-03-08 DOI: 10.1016/j.tem.2025.02.002
Nathaniel F Henneman, Ganna Panasyuk
{"title":"Enhancer binding as a KEysTONE of fasting response.","authors":"Nathaniel F Henneman, Ganna Panasyuk","doi":"10.1016/j.tem.2025.02.002","DOIUrl":"10.1016/j.tem.2025.02.002","url":null,"abstract":"<p><p>Fasting is a recurrent daily energy stress that benefits healthspan and lifespan. While ketones fuel fasting in vertebrates, the underlying transcriptional mechanism remains incompletely understood. Recently, Korenfeld et al. revealed peroxisome proliferator-activated receptor alpha (PPARα)-dependent enhancer priming as a keystone for ketone production, increasing our understanding of mechanisms underlying metabolic benefits of alternate-day fasting (ADF).</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"298-300"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11979617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do weight loss interventions challenge the obesity paradox in heart failure? 减肥干预是否挑战了心力衰竭中的肥胖悖论？
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2025-02-11 DOI: 10.1016/j.tem.2025.01.006
Salva R Yurista, Robert A Eder, W Scott Butsch, Ivan Luptak
{"title":"Do weight loss interventions challenge the obesity paradox in heart failure?","authors":"Salva R Yurista, Robert A Eder, W Scott Butsch, Ivan Luptak","doi":"10.1016/j.tem.2025.01.006","DOIUrl":"10.1016/j.tem.2025.01.006","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) remains a significant global health concern, with obesity recognized as a prominent risk factor. The 'obesity paradox' (OP) suggests that obesity does not always lead to adverse outcomes, particularly in heart failure (HF). In this forum, we discuss the relevance of the OP in the current therapeutic landscape for cardiometabolic diseases.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"295-297"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic management of obesity and metabolic diseases. 肥胖症和代谢性疾病的内镜治疗。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2024-11-29 DOI: 10.1016/j.tem.2024.11.001
Trent Walradt, Pichamol Jirapinyo
{"title":"Endoscopic management of obesity and metabolic diseases.","authors":"Trent Walradt, Pichamol Jirapinyo","doi":"10.1016/j.tem.2024.11.001","DOIUrl":"10.1016/j.tem.2024.11.001","url":null,"abstract":"<p><p>Obesity has become a global pandemic that is associated with a range of metabolic disorders. Traditional treatment options, such as lifestyle modification and anti-obesity medications, often exhibit limited efficacy and can lead to long-term weight gain, especially upon discontinuation of the medication. Although bariatric surgery is effective, its accessibility is constrained, and only a small percentage of eligible patients receive this intervention. Over the past two decades, endoscopic bariatric and metabolic therapies (EBMTs) have emerged as minimally invasive and effective alternatives for managing obesity and its related comorbidities. This article reviews primary gastric and small bowel EBMTs, their mechanisms of action, key supporting literature, and the metabolic outcomes associated with each device and procedure.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"373-385"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like peptide-1 receptor agonism and end-organ protection. 胰高血糖素样肽-1受体激动作用和终末器官保护。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2025-02-10 DOI: 10.1016/j.tem.2025.01.002
Samuel Daniels, Cecilia Karlsson, Patrick Schrauwen, Victoria E R Parker
{"title":"Glucagon-like peptide-1 receptor agonism and end-organ protection.","authors":"Samuel Daniels, Cecilia Karlsson, Patrick Schrauwen, Victoria E R Parker","doi":"10.1016/j.tem.2025.01.002","DOIUrl":"10.1016/j.tem.2025.01.002","url":null,"abstract":"<p><p>Identification of exendin-4 (a glucagon-like peptide-1 receptor agonist, GLP-1RA) in Gila monster venom may be regarded as one of the most serendipitous discoveries of recent times. GLP-1RAs are now an established therapeutic approach in type 2 diabetes (T2D), body weight management, and cardiovascular (CV) risk protection. Furthermore, there is a growing platform of evidence that GLP-1RA has extended benefit in renal, hepatic, respiratory, and neurological diseases. One can speculate on the biological advantage of exendin-4 to the Gila monster, but for humankind GLP-1RAs are peptides with significant potential to improve disease-related outcomes. We report on the latest evidence and mechanisms for GLP-1RA-mediated end-organ protection that uniquely highlight its future development potential across multiple disease areas.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"301-315"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The unexpected role of GIP in transforming obesity treatment. GIP 在改变肥胖症治疗方面发挥了意想不到的作用。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-04-01 Epub Date: 2024-08-27 DOI: 10.1016/j.tem.2024.07.022
Inuk Zandvakili, Diego Perez-Tilve
{"title":"The unexpected role of GIP in transforming obesity treatment.","authors":"Inuk Zandvakili, Diego Perez-Tilve","doi":"10.1016/j.tem.2024.07.022","DOIUrl":"10.1016/j.tem.2024.07.022","url":null,"abstract":"<p><p>Despite sharing incretin activity with glucagon-like peptide 1 (GLP-1), the development of gastric inhibitory polypeptide (GIP)-based drugs has been hindered by the minor effects of native GIP on appetite and body weight and genetic studies associating loss-of-function with reduced obesity. Yet, pharmacologically optimized GIP-based molecules have demonstrated profound weight lowering benefits of GIPR agonism when combined with GLP-1-based therapies, which has re-energized deeper exploration of the molecular mechanisms and downstream signaling of GIPR. Interestingly, both GIPR agonism and antagonism offer metabolic benefits, leading to differing viewpoints on how to target GIPR therapeutically. Here we summarize the emerging evidence about the tissue-specific mechanisms that positions GIP-based therapies as important targets for the next generation of anti-obesity and metabolic therapies.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"330-338"},"PeriodicalIF":11.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hidden players in the metabolic vulnerabilities of amyotrophic lateral sclerosis. 肌萎缩性侧索硬化症代谢脆弱性的隐藏参与者。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2025-03-15 DOI: 10.1016/j.tem.2025.02.004
Marco Rosina, Silvia Scaricamazza, Gianmarco Fenili, Valentina Nesci, Cristiana Valle, Alberto Ferri, Maria Paola Paronetto
{"title":"Hidden players in the metabolic vulnerabilities of amyotrophic lateral sclerosis.","authors":"Marco Rosina, Silvia Scaricamazza, Gianmarco Fenili, Valentina Nesci, Cristiana Valle, Alberto Ferri, Maria Paola Paronetto","doi":"10.1016/j.tem.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.tem.2025.02.004","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a complex and rapidly progressive motor neuron disorder with a fatal outcome. Despite the remarkable progress in understanding ALS pathophysiology, which has significantly contributed to clinical trial design, ALS remains a rapidly disabling and life-shortening condition. The non-motor neuron features of ALS, including nutritional status, energy expenditure, and metabolic imbalance, are increasingly gaining attention. Indeed, the bioenergetic failure and mitochondrial dysfunction of patients with ALS impact not only the high energy-demanding motor neurons but also organs and brain areas long considered irrelevant to the disease. As such, here we discuss how considering energy balance in ALS is reshaping research on this disease, opening the path to novel targetable opportunities for its treatment.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信